Quarterly Report · 10-Q

Relay Therapeutics, Inc.

RLAYNASDAQEQUITYCurrent

Quarterly Report

Filed Aug 6, 2026Accepted Aug 6, 2026, 4:15 PM EDTCIK 1812364Accession 0001193125-26-338056

Company context

Relay Therapeutics (Nasdaq: RLAY) is a clinical-stage, small molecule precision medicine company developing potentially life-changing therapies for patients living with cancer and genetic disease. Relay Therapeutics’ Dynamo® platform integrates an array of leading-edge computational and experimental approaches designed to drug protein targets that have previously been intractable or inadequately addressed. Relay Therapeutics’ lead clinical asset, zovegalisib, is the first pan-mutant selective PI3Kα inhibitor to enter clinical development and is currently in a Phase 3 clinical trial (ReDiscover-2) in HR+/HER2- metastatic breast cancer. Zovegalisib is also being investigated in a group of genetic disease indications called PI3Kα-driven vascular anomalies. Relay Therapeutics’ pipeline also includes programs

Current securities

RLAYNASDAQ · EQUITY · Current

Recent company filings

Registered securities in this filing

RELAY THERAPEUTICS, INC. · 10-Q · Filed 2026-08-06

As filed in this accession. Current/historical status below comes from the governed listing record; the cover itself remains exact to this filing.

Common Stock, par value $0.001 per share

Symbol: RLAY
Exchange: NASDAQ
Classification: COMMON
Status: Current

Filing context

Context: C_3cca5011-adb3-4f7a-8724-c41042ce161c

Dimensions: Not supplied

Accession 000119312526338056 · 1 registered-security cover member

Read the exact SEC filing ↗

As-filed source

Primary evidence

As filedOpen full document ↗

Get the free weekly BCS email.